Press release
Global Irritable Bowel Syndrome Treatment Market Strategical Analysis Report 2022
The primary purpose of the statistical analysis is to use data analysis and descriptive statistics. It helps to summarize data from a sample using indexes like mean or standard deviation and inferential statistics. This report includes information and statistics on price levels, location of the product, and demand for the product. The best thing about the statistical analysis report is that it allows businesses to make decisions in terms of consumer preferences and purchasing power. Moreover, it provides demographic information like the number of potential customers in a geographical area, income level, consumer preferences, and much more. With the help of Irritable Bowel Syndrome Treatment Market statistical analysis, the market could get crucial information on how the collected data and samples will be analyzed.Irritable Bowel Syndrome Treatment Market is expected to reach US$ 7.3 Bn by the end of 2031, with sales revenue expected to register 8.7% CAGR.
Get Free Sample Copy of this Report@ https://www.persistencemarketresearch.com/samples/9938
As per Persistence Market Research's latest industry analysis, the global irritable bowel syndrome treatment market was valued at over US$ 2.9 Bn in 2020, and is expected to exhibit a CAGR of around 8.7% over the forecast period (2021-2031)
According to the Journal of Gastroenterology published in April 2020, approximately 11% of the people in the world are living with gastrointestinal issues such as irritable bowel syndrome. Various other gastrointestinal-related problems arise with irritable bowel syndrome, such as IBS with constipation (IBS-C), IBS with diarrhoea (IBS-D), and IBS with mixed bowel habits (IBS-M).
Rising prevalence of gastrointestinal disorders and irritable bowel syndrome has led to increased government engagement for the treatment of IBS. This is due to substantial economic burden of irritable bowel syndrome on the healthcare system. As per BMC Gastroenterology (2020), the direct cost of diagnosis and treatment of irritable bowel syndrome in the U.S. is estimated to be between US$ 1.7 Bn and US$ 10 Bn, annually.
Key players are focusing on expansion in emerging regions and new revised product manufacturing. The strategy of expansion, new product launches, and approvals by key manufacturers is further strengthening their market presence.
In May 2019, Allergan and Ironwood launched an interactive digital destination "AboutYourGut.com" website to promote awareness regarding irritable bowel syndrome, and to provide comfort to people going through it. The website also contains facts and figures associated with multiple forms of irritable bowel syndrome (IBS-D, IBS-C, and IBS-M)
In August 2020, Takeda received EMA approval for the subcutaneous formulation of its Inflammatory Bowel Disease (IBD) drug "Entyvio", thus increasing its product range as well as geographical footprint.
Company Profiles:
Takeda Pharmaceutical Company Limited, Pfizer, Inc., Abbott Laboratories, Novartis AG, AstraZeneca PLC, Ironwood Pharmaceuticals Inc. and Allergan Plc, Bausch Health Companies Inc., GlaxoSmithKline, Plc., Lexicon Pharmaceuticals, Inc., Sucampo Pharmaceuticals, Inc.
Request for Methodology@ https://www.persistencemarketresearch.com/methodology/9938
irritable-bowel-syndrome-treatment-market
Key Takeaways from Market Study
By drug type, Linaclotide is expected to hold 19.5% market value share by the end of 2031.
Based on indication, irritable bowel syndrome with constipation is a leading factor with over 48% market share.
Retail pharmacies dominated the market with a share of 30.3% in 2020. Accessibility of drugs for the treatment of irritable bowel syndrome as well as ease and availability of dispensing add to the growing demand from retail pharmacies.
By region, North America is set dominate the global market with a value share of around 41.7% by end of 2031. Europe is slated to be the second-largest leading region with a value share of 30.1%.
"Growing prevalence of gastrointestinal diseases, rising initiatives by governments for the management of IBS, and strategic collaborations & acquisitions by key players are set to drive market growth," says an analyst of Persistence Market Research.
Access Full Report@ https://www.persistencemarketresearch.com/checkout/9938
Market Competition
Agreements, collaborations, and partnerships have emerged as key growth strategy adopted by industry players. By focusing on these strategies, key stakeholders are expanding their geographic footprints and strengthening their existing product portfolios.
In March 2019, Bausch Health Companies Inc. announced the acquisition of certain assets of Synergy Pharmaceuticals Inc., including the addition of TRULANCE® to its product portfolio, which is a tablet approved for adults with irritable bowel syndrome and chronic idiopathic constipation.
In September 2019, AstraZeneca gained sole responsibility for developing, manufacturing, and marketing an irritable bowel syndrome drug in China, through an amended collaboration agreement with Ironwood Pharmaceuticals.
What Does the Report Cover?
Persistence Market Research offers a unique perspective and actionable insights on the irritable bowel syndrome treatment market in its latest study, presenting historical demand assessment of 2016 - 2020 and projections for 2021 - 2031.
Media Contact:
Persistence Market Research
305 Broadway,7th Floor New York City, NY 10007 United States
Call +1-646-568-7751
Call +1 800-961-0353
sales@persistencemarketresearch.com
About Us:
Persistence Market Research is here to provide companies a one-stop solution with regards to bettering customer experience. It does engage in gathering appropriate feedback after getting through personalized customer interactions for adding value to customers' experience by acting as the "missing" link between "customer relationships" and "business outcomes'. The best possible returns are assured therein.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Global Irritable Bowel Syndrome Treatment Market Strategical Analysis Report 2022 here
News-ID: 2779160 • Views: …
More Releases from Persistence Market Research

Microelectronic Medical Implants Market Size to Hit USD 98.5 Billion in 2032, ex …
The microelectronic medical implants market plays a pivotal role in advancing modern healthcare by integrating electronics into medical devices to restore or enhance physiological functions. These implants are widely used in cardiology, neurology, orthopedics, and sensory assistance, including pacemakers, cochlear implants, neurostimulators, and insulin pumps. By offering precise monitoring, stimulation, and drug delivery, microelectronic implants significantly improve patient outcomes, quality of life, and long-term disease management.
Request a Sample: https://www.persistencemarketresearch.com/samples/33122
According to…

Dental Adhesives Market Worth US$ 4,052.8 Million By 2032, PMR Report
The dental adhesives market plays a critical role in modern dentistry by improving the durability, effectiveness, and esthetic outcomes of restorative and preventive dental procedures. Dental adhesives are extensively used in applications such as composite restorations, dental sealants, orthodontic bonding, and prosthodontics. They enhance adhesion between dental tissues and restorative materials, ensuring long-lasting results while minimizing microleakage, sensitivity, and secondary caries.
Request a Sample:
https://www.persistencemarketresearch.com/samples/33315
According to the latest study by Persistence…

Wound Sprays Market Set to Soar to $694.5 Million by 2032 , Persistence Market R …
The wound sprays market plays a crucial role in modern healthcare by providing rapid, convenient, and effective solutions for wound management. Wound sprays are extensively used in hospitals, clinics, emergency care, and home healthcare settings to prevent infections, accelerate healing, and improve patient comfort. They are particularly valuable for cuts, abrasions, burns, surgical incisions, and chronic wounds.
Request a Sample:
https://www.persistencemarketresearch.com/samples/33306
According to the latest study by Persistence Market Research, The global…

Surgical Instrument Tracking System Market Poised for 14.2% CAGR Growth by 2033
The surgical instrument tracking system market plays a pivotal role in enhancing the efficiency, safety, and accountability of surgical operations. These systems are widely deployed in hospitals, surgical centers, and clinics to manage surgical instruments, monitor their usage, and ensure sterilization compliance. By providing real-time tracking and inventory management, surgical instrument tracking systems reduce operational errors, prevent infections, and streamline surgical workflows.
For More Information:
https://www.persistencemarketresearch.com/market-research/surgical-instrument-tracking-system-market.asp
According to the latest study by Persistence…
More Releases for IBS
Irritable Bowel Syndrome (IBS) Treatment Market Poised to Hit $7.68B by 2033 | S …
The Global Irritable Bowel Syndrome (IBS) Treatment Market reached US $3.61 billion in 2024 and is forecast to nearly double to US $7.68 billion by 2033, growing at a robust 8.8% CAGR from 2025 to 2033, according to DataM Intelligence's comprehensive report. IBS affects an estimated 5-10% of the global population, marking it one of the most prevalent gastrointestinal disorders with significant unmet medical needs.
👉 Download our latest market insights:…
Integrated Bridge Systems Market Report 2018: Segmentation by Platform (Commerci …
Global Integrated Bridge Systems market research report provides company profile for Northrop Grumman Sperry Marine (U.K.), Raytheon Anschütz (Germany), Rolls Royce (U.K.), L-3 Communications Mapps Inc. (Canada), FURUNO Electric Shokai Ltd. (Japan) and Others.
This market study includes data about consumer perspective, comprehensive analysis, statistics, market share, company performances (Stocks), historical analysis 2012 to 2017, market forecast 2018 to 2025 in terms of volume, revenue, YOY growth rate, and CAGR…
IBS' solution to power China’s first Cruise Line
Trivandrum, 16 January 2013: Henna, the largest cruise ship in mainland China will run on IBS’ inventory and pricing management solution, Cruise Partner, when it makes its maiden journey on January 26, 2013. China based HNA Tourism Cruise and Yacht Management Company unveiled this cruise ship on November 28, 2012. Henna has 739 rooms for 1,965 passengers, as well as a complete range of facilities for living and entertainment. HNA…
Vikash Sureka joins IBS as Chief Financial Officer
Trivandrum (India), 17 May 2012: IBS Software Services, the leading provider of new-generation IT solutions to the global aviation industry, has appointed Mr Vikash Sureka as its Chief Financial Officer. He will head the Finance, Legal, Company Affairs and Administration functions of IBS operations world-wide.
A Chartered Accountant, Vikash has over 19 years of experience mostly in senior executive roles managing business globally with proven proficiency in Investor Relations, P&L…
HaCon and IBS combine expertise in railway operation
Hanover (2010-07-06). Two Hanoverian companies now combine their expertise in questions of railway operations: With effect from 1 July 2010, the HaCon Ingenieurgesellschaft mbH, took over the engineering firm for railway operating systems (Ingenieurbüro für Bahnbetriebssysteme GmbH – IBS). This way HaCon expanded its services to include the areas operation simulation, vehicle and personnel planning and construction operations planning.
This also includes consulting services concerning railway systems issues, such as travel…
Raytheon Anschütz IBS for new Intership Bulkers
Raytheon Anschütz was recently awarded a contract to supply their Integrated Bridge System (IBS) to two new bulk carriers. The bulkers will be built at New Times Shipyard in Jingjiang, China. The delivery to the Cyprus based shipping company Intership Navigation Co. Ltd., a member of the German Hartmann Group, is scheduled for August and October 2011.
The new bulkers, each with a capacity of 176,000 dwt, will be equipped…